Skip to main content

Promega to Co-Develop Drug-Screening Assays With Chinese Institute

NEW YORK (GenomeWeb News) — Promega and China’s Guangzhou Institute of Biomedicine and Health plan to co-develop drug-screening assays, the company said today. 
 
Under the agreement, GIBH researchers will use Promega’s drug-screening assays to develop tests for Cytochrome P450, Kinase, and GPCR profiling.
 
Promega said GIBH, which is part of the Chinese Academy of Sciences, will use the assays for their own research and will offer them through contracts to other companies.
 
Financial terms of the agreement were not released.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.